Clinical Trials Browser

Neoplasms, Second Primary × avelumab × 1 year × Clear all

NCT05217069 2025-04-16

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Phase 2 Completed

Neoplasms, Second Primary